Diagnostic accuracy of first-trimester free b-HCG and pregnancy-associated plasma protein-A assays
In a recent article, 1 Dr Kevin Spencer summarized a study comparing the DPC IMMULITE s 2000 free b-HCG and PAPP-A assays to the corresponding Brahms Kryptor assays. The article focuses on clinical performance indices --observed and estimated detection rates for Down's syndrome (DS) --relevant to ¢rst-trimester maternal screening programmes that combine these two biochemical markers with nuchal translucency (NT) ultrasound measurements.
Sixty frozen samples from DS pregnancies and 813 fresh samples from normal ¢rst-trimester pregnancies were used for the clinical study. The former evidently constitute a subset (29%) of a larger series of 210 DS samples; just how the 60 were selected for the smaller study is not described.
In the smaller series, reported in this article, the IMMULITE 2000 and Kryptor assays yielded detection rates of 58% and 62%, respectively, for the DS cases. In the larger series, the Kryptor assays had yielded a somewhat higher detection rate of 67%.
Given that results in the smaller study are indeed representative of the larger, the Kryptor detection rates observed in the two studies provide a basis for estimating how the IMMULITE 2000 assays would have performed in the larger series. Adjusting the IMMULITE 2000 detection rate observed for the smaller series either by the di¡erence between the Kryptor rates or by their ratio --that is, adding (67% minus 62%) to 58%, or else multiplying 58% by (67% divided by 62%) --yields 63% as the reader's best estimate for the IMMULITE 2000 detection rate in the larger series.
The rates quoted above were determined without recourse to NT measurements, which would always be available in routine practice. Accordingly, the author extrapolates from the data by mathematical modelling to predict, for the same samples, detection rates of 85% and 87% ( ¼89% minus 2%) for the IMMULITE 2000 and Kryptor results, respectively, used in combination with NT data. These rates correspond to detecting 51 and 52 DS cases out of 60: a di¡erence of just one sample.
Accordingly, there are three pairs of contrasting detection rates supported by the data and the data analyses in the article:
(1) 58% versus 62% --observations for the IMMULITE 2000 and Kryptor assays in the smaller series; (2) 85% versus 87% --estimates for the IMMULITE 2000 and Kryptor assays in the smaller series, taking NT measurements into account; and (3) 63% versus 67% --performance in the larger series estimated for the IMMULITE 2000 assays, observed for the Kryptor assays.
Of these, only (1) and (2) represent comparisons between the DPC and Brahms assays made on essentially the same basis. (3), which does not ¢gure in the article, would involve comparing estimates with observations, and there is even less warrant for other contrasts which might be drawn. The detection rate observed for the IMMULITE 2000 assays in the smaller series (58%), for example, cannot justi¢ably be compared with the Kryptor rate observed in the larger series (67%), nor can the rate estimated for the IMMU-LITE 2000 assays taking NT measurements into account in the smaller study (85%) be compared directly with a value for the Kryptor assays in a larger series.
Restricting attention, therefore, to the warranted comparisons, the question naturally arises whether response in production of this protein to the administration of the extra Cu. If this patient had an issue relating to protein metabolism, then this would not have been the case and both plasma Cu and caeruloplasmin concentrations would have remained low.
Case 2 did not show the same rise in plasma Cu and caeruloplasmin as Case 1, and only showed a small response when extra copper supplementation was given at a time di¡erent from other medication. The carer for this patient was concerned about the increased bowel movements associated with the administration of the Minedex solution, which contains iron and manganese in addition to copper. We suspect that the extra supplemental Cu was not being administered with the same regularity in Case 2 as in Case 1. There are certainly no reasons to suspect any issues relating to protein synthesis in Case 2. This latter patient was on enteral feeding following a CVA and had no previous medical history of note, with normal renal and liver function tests and a normal plasma albumin. Case 1, on the other hand, was a very frail elderly lady with a history of liver disease, who has recently died. We do intend to follow up Case 2 by carrying out an isotopic Cu 65 absorption test. I agree with Twomey et al. that low plasma Cu concentrations per se are not necessarily due to copper de¢ciency. However, patients with low plasma Cu due to copper de¢ciency also have associated low plasma concentrations of caeruloplasmin.
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Restricting attention, therefore, to the warranted comparisons, the question naturally arises whether the di¡erence between the detection rates (58% and 62%) observed for the two systems of assays in the smaller series is actually signi¢cant, and likewise for the di¡erence between the rates (85% and 87%) estimated for the real-world situation in which NT measurements would be available.
The answer to both questions is evidently 'no'. The observed and estimated di¡erences are small, and readers may well suspect --rightly, in this instance --that a series of only 60 DS cases cannot rule out sampling variation as an explanation for the apparent di¡erences.
The article supplies only point estimates for the detection rates in question, even though it is now generally accepted 2 that con¢dence intervals (CIs) 'should be stated, particularly for nonsigni¢cant results'. No CIs, P-values or other measures are recorded from which the signi¢cance or non-signi¢cance of the stated di¡erences could be read o¡ directly.
Fortunately, there is enough information for a reader to calculate CIs, thereby con¢rming the conclusions left implicit in the article, namely that the detection rates observed and estimated in this study for the IMMULITE 2000 assays were not signi¢cantly lower than those for the Kryptor assays. (In fact, the article does not assert that di¡erences between the IMMULITE 2000 and Kryptor detection rates are statistically signi¢cant.)
The 95% CIs listed below, in parentheses, for the relevant detection rates quoted in Dr Spencer's article, and for their di¡erences, were calculated according to current recommendations:Wilson's method for a proportion and Newcombe's method for a di¡erence in proportions. CIs tabulated here for the di¡erences were calculated on a paired basis, by assuming that the IMMU-LITE 2000 assays detected no DS cases not also detected by the Kryptor assays. This is inherently more favourable to the Kryptor assays than an unpaired analysis, in the sense of yielding narrower CIs and thus a greater tendency to certify the detection rates observed or estimated for the Kryptor assays as signi¢cantly higher. But even on this basis, no signi¢-cant di¡erence between the two assay systems can be demonstrated from the results of the clinical study reported in Dr Spencer's article, as the statistics tabulated above attest.
CIs for the detection rates are evidently very broad, largely because of the relatively small number of DS cases involved. CIs for the di¡erences both straddle zero --indeed, zero falls well within the interior of each interval --meaning that the apparent di¡erences in detection rates can not be regarded as signi¢cant at a 95% probability level (or even at considerably lower levels).
In short, the clinical results assembled by Dr Spencer in the present article fail to demonstrate, according to the prevailing standards of evidence-based laboratory medicine, that the DPC assays are signi¢cantly di¡erent from the Brahms assays with respect to the measure of diagnostic accuracy most relevant in this context, namely, ¢rst-trimester detection rates for DS. 
